Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
26 6월 2008 - 8:30PM
PR Newswire (US)
Study Meets Primary Endpoint, with Positive Effect Sustained
Through Duration of 4-Week Study ROCKVILLE, Md., June 26
/PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
(Vanda) today announced positive top-line results from a Phase III
trial showing that its investigational drug candidate, tasimelteon
(VEC-162), a novel melatonin agonist, met the primary endpoint of
the trial and significantly improved sleep in adult patients with
chronic insomnia. "We are excited that the results of this Phase
III chronic insomnia study demonstrate the clinical utility of
tasimelteon and the ability of the compound to treat sleep
disorders over a period of four weeks. The mechanism of action of
tasimelteon as a circadian regulator gives Vanda the opportunity to
explore its use for the treatment of circadian rhythm sleep
disorders as well as chronic primary insomnia," stated Paolo
Baroldi, MD, PhD, Vanda's Chief Medical Officer. This Phase III,
multi-center, placebo-controlled, 4-week trial evaluated 322
patients with chronic primary insomnia. Patients were randomized to
receive either 20 mg or 50 mg of tasimelteon or placebo over the
course of four weeks. The primary endpoint consisted of the
evaluation of the immediate and short-term (average of Nights 1 and
8) ability of tasimelteon to improve sleep onset as measured by
Latency to Persistent Sleep (LPS) through polysomnography (PSG).
Secondary endpoints evaluated tasimelteon's ability to maintain
improvements on sleep onset after long-term (average of Nights 22
and 29) use of the compound as well as measures of sleep duration
(Total Sleep Time, TST) and sleep maintenance (Wake After Sleep
Onset, WASO). Patients were eligible for the study if symptoms of
insomnia were chronic and LPS was greater than 30 minutes.
Significant Improvement in Sleep Onset Sustained through Study
Duration These results demonstrate that tasimelteon was able to
improve LPS significantly, and that this effect persisted for the 4
week duration of the study. The results on LPS at night 1
(N1)/night 8 (N8), and night 22 (N22)/night 29 (N29) are as
follows. -- Mean LPS at baseline (before drug treatment) was 78.8
minutes in the 20mg group, 76.4 minutes in the 50mg group, and 78.2
minutes in the placebo group. On Nights 1 and 8 of treatment, mean
LPS improved by 45.0 minutes in the 20mg group (p
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024